Trial Profile
An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype 1 virus infection in patients with HIV-1 co-infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2016
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CHAT
- Sponsors Janssen-Cilag
- 31 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 04 Oct 2013 New trial record